Autolus Therapeutics (AUTL) Share-based Compensation (2018 - 2025)
Autolus Therapeutics' Share-based Compensation history spans 5 years, with the latest figure at $3.4 million for Q4 2025.
- For Q4 2025, Share-based Compensation fell 44.76% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $14.4 million, down 6.68%, while the annual FY2025 figure was $14.4 million, 6.68% down from the prior year.
- Share-based Compensation reached $3.4 million in Q4 2025 per AUTL's latest filing, down from $3.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $6.2 million in Q4 2024 to a low of -$8.6 million in Q4 2022.
- Average Share-based Compensation over 4 years is $2.5 million, with a median of $2.9 million recorded in 2024.
- Peak YoY movement for Share-based Compensation: skyrocketed 138.09% in 2023, then plummeted 44.76% in 2025.
- A 4-year view of Share-based Compensation shows it stood at -$8.6 million in 2022, then surged by 138.09% to $3.3 million in 2023, then surged by 90.32% to $6.2 million in 2024, then tumbled by 44.76% to $3.4 million in 2025.
- Per Business Quant, the three most recent readings for AUTL's Share-based Compensation are $3.4 million (Q4 2025), $3.8 million (Q3 2025), and $4.3 million (Q2 2025).